Randomized Trialhigh evidence
Heart Rate Variability Biofeedback for Substance Use Disorder: A Randomized Clinical Trial.
JAMA psychiatry·December 1, 2025·PMID 41032322
Why it mattersFor clinicians treating substance use disorder, this suggests a wearable biofeedback intervention may provide a practical adjunct to standard outpatient care by targeting craving and affect regulation, not just self-reported wellness, with signal for reduced substance use.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled